Encephalopathy following subcutaneous administration of Brixadi® extended-release buprenorphine
Justin Seltzer, Riku Moriguchi, Kara Yeung, Yuri Shindo, Jeremy Hardin, Henrik Galust, Alicia Minns, Richard Clark · 2026
Read Encephalopathy following subcutaneous administration of Brixadi® extended-release buprenorphine by Justin Seltzer, Riku Moriguchi, Kara Yeung, Yuri Shindo, Jeremy Hardin, Henrik Galust, Alicia Minns, Richard Clark (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13451788.txt.
Description
Justin Seltzer and co-authors report in 2026 a case of clouded thinking after a long-acting shot used for opioid use disorder. The shot, Brixadi, gives a month of buprenorphine under the skin. Their patient, aged 62, arrived with three days of changed alertness after getting the shot at an addiction clinic.
She had grown sleepy and muddled within two hours of the shot, and tests and brain scans found no other clear cause. The next day her breathing slowed and her pupils shrank, signs that fit opioid effects. Reversal drugs gave short-lived gains. The case warns clinics to watch for this rare brain effect after the shot, even at standard doses.
Catalog record
| CREATOR | Justin Seltzer, Riku Moriguchi, Kara Yeung, Yuri Shindo, Jeremy Hardin, Henrik Galust, Alicia Minns, Richard Clark |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 11748 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |